These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 15860572

  • 1. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
    Hennan JK, Elokdah H, Leal M, Ji A, Friedrichs GS, Morgan GA, Swillo RE, Antrilli TM, Hreha A, Crandall DL.
    J Pharmacol Exp Ther; 2005 Aug; 314(2):710-6. PubMed ID: 15860572
    [Abstract] [Full Text] [Related]

  • 2. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
    Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, Penn MS.
    Thromb Haemost; 2010 Sep; 104(3):609-17. PubMed ID: 20694285
    [Abstract] [Full Text] [Related]

  • 3. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
    Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ.
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
    [Abstract] [Full Text] [Related]

  • 5. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 6. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ.
    J Pharmacol Exp Ther; 1999 Apr 04; 289(1):503-10. PubMed ID: 10087043
    [Abstract] [Full Text] [Related]

  • 7. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
    Rupin A, Martin F, Vallez MO, Bonhomme E, Verbeuren TJ.
    Thromb Haemost; 2001 Dec 04; 86(6):1528-31. PubMed ID: 11776323
    [Abstract] [Full Text] [Related]

  • 8. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ.
    J Pharmacol Exp Ther; 1988 Aug 04; 246(2):790-6. PubMed ID: 3136245
    [Abstract] [Full Text] [Related]

  • 9. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
    Matsuno H, Kozawa O, Niwa M, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Thromb Haemost; 1999 Apr 04; 81(4):601-4. PubMed ID: 10235447
    [Abstract] [Full Text] [Related]

  • 10. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
    Matsuno H, Kozawa O, Ueshima S, Matsuo O, Collen D, Uematsu T.
    Br J Pharmacol; 2000 Oct 04; 131(4):858-64. PubMed ID: 11030738
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY, Nichols WW, Mattsson C, Teger-Nilson AC, Wallin R, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1995 Dec 04; 30(6):866-74. PubMed ID: 8746200
    [Abstract] [Full Text] [Related]

  • 15. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
    Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott MJ, Stranieri MT, Stabilito II, Zhang G, Lynch RJ.
    J Pharmacol Exp Ther; 1995 Jan 04; 272(1):20-32. PubMed ID: 7815334
    [Abstract] [Full Text] [Related]

  • 16. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR.
    J Pharmacol Exp Ther; 2001 Feb 04; 296(2):567-72. PubMed ID: 11160645
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
    Jackson CV, Bailey BD, Shetler TJ.
    J Pharmacol Exp Ther; 2000 Dec 04; 295(3):967-71. PubMed ID: 11082430
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
    Fiedler VB, Perzborn E, Seuter F, Rosentreter U, Böshagen H.
    Arzneimittelforschung; 1989 Dec 04; 39(12):1527-30. PubMed ID: 2624600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.